Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Small interfering RNAs based on huntingtin trinucleotide repeats are highly toxic to cancer cells.

Murmann AE, Gao QQ, Putzbach WE, Patel M, Bartom ET, Law CY, Bridgeman B, Chen S, McMahon KM, Thaxton CS, Peter ME.

EMBO Rep. 2018 Mar;19(3). pii: e45336. doi: 10.15252/embr.201745336. Epub 2018 Feb 12.

PMID:
29440125
2.

DISE: A Seed-Dependent RNAi Off-Target Effect That Kills Cancer Cells.

Putzbach W, Gao QQ, Patel M, Haluck-Kangas A, Murmann AE, Peter ME.

Trends Cancer. 2018 Jan;4(1):10-19. doi: 10.1016/j.trecan.2017.11.007. Epub 2018 Jan 8. Review.

PMID:
29413418
3.

Induction of DISE in ovarian cancer cells in vivo.

Murmann AE, McMahon KM, Haluck-Kangas A, Ravindran N, Patel M, Law CY, Brockway S, Wei JJ, Thaxton CS, Peter ME.

Oncotarget. 2017 Oct 4;8(49):84643-84658. doi: 10.18632/oncotarget.21471. eCollection 2017 Oct 17.

4.

Many si/shRNAs can kill cancer cells by targeting multiple survival genes through an off-target mechanism.

Putzbach W, Gao QQ, Patel M, van Dongen S, Haluck-Kangas A, Sarshad AA, Bartom ET, Kim KA, Scholtens DM, Hafner M, Zhao JC, Murmann AE, Peter ME.

Elife. 2017 Oct 24;6. pii: e29702. doi: 10.7554/eLife.29702.

5.

CD95/Fas Increases Stemness in Cancer Cells by Inducing a STAT1-Dependent Type I Interferon Response.

Qadir AS, Ceppi P, Brockway S, Law C, Mu L, Khodarev NN, Kim J, Zhao JC, Putzbach W, Murmann AE, Chen Z, Chen W, Liu X, Salomon AR, Liu H, Weichselbaum RR, Yu J, Peter ME.

Cell Rep. 2017 Mar 7;18(10):2373-2386. doi: 10.1016/j.celrep.2017.02.037.

6.

The role of CD95 and CD95 ligand in cancer.

Peter ME, Hadji A, Murmann AE, Brockway S, Putzbach W, Pattanayak A, Ceppi P.

Cell Death Differ. 2015 May;22(5):885-6. doi: 10.1038/cdd.2015.25. No abstract available.

7.

The role of CD95 and CD95 ligand in cancer.

Peter ME, Hadji A, Murmann AE, Brockway S, Putzbach W, Pattanayak A, Ceppi P.

Cell Death Differ. 2015 Apr;22(4):549-59. doi: 10.1038/cdd.2015.3. Epub 2015 Feb 6. Review. Erratum in: Cell Death Differ. 2015 May;22(5):885-6.

8.

CD95 and CD95L promote and protect cancer stem cells.

Ceppi P, Hadji A, Kohlhapp FJ, Pattanayak A, Hau A, Liu X, Liu H, Murmann AE, Peter ME.

Nat Commun. 2014 Nov 4;5:5238. doi: 10.1038/ncomms6238.

9.

Death induced by CD95 or CD95 ligand elimination.

Hadji A, Ceppi P, Murmann AE, Brockway S, Pattanayak A, Bhinder B, Hau A, De Chant S, Parimi V, Kolesza P, Richards J, Chandel N, Djaballah H, Peter ME.

Cell Rep. 2014 Apr 10;7(1):208-22. doi: 10.1016/j.celrep.2014.02.035. Epub 2014 Mar 20.

10.

MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer.

Mitra AK, Zillhardt M, Hua Y, Tiwari P, Murmann AE, Peter ME, Lengyel E.

Cancer Discov. 2012 Dec;2(12):1100-8. doi: 10.1158/2159-8290.CD-12-0206. Epub 2012 Nov 21.

11.

miRConnect: identifying effector genes of miRNAs and miRNA families in cancer cells.

Hua Y, Duan S, Murmann AE, Larsen N, Kjems J, Lund AH, Peter ME.

PLoS One. 2011;6(10):e26521. doi: 10.1371/journal.pone.0026521. Epub 2011 Oct 26.

12.

Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1.

Boyerinas B, Park SM, Murmann AE, Gwin K, Montag AG, Zillhardt M, Hua YJ, Lengyel E, Peter ME.

Int J Cancer. 2012 Apr 15;130(8):1787-97. doi: 10.1002/ijc.26190. Epub 2011 Aug 16.

13.

miR-200c regulates induction of apoptosis through CD95 by targeting FAP-1.

Schickel R, Park SM, Murmann AE, Peter ME.

Mol Cell. 2010 Jun 25;38(6):908-15. doi: 10.1016/j.molcel.2010.05.018.

14.

The role of let-7 in cell differentiation and cancer.

Boyerinas B, Park SM, Hau A, Murmann AE, Peter ME.

Endocr Relat Cancer. 2010 Jan 29;17(1):F19-36. doi: 10.1677/ERC-09-0184. Print 2010 Mar. Review.

15.

Inverted duplications on acentric markers: mechanism of formation.

Murmann AE, Conrad DF, Mashek H, Curtis CA, Nicolae RI, Ober C, Schwartz S.

Hum Mol Genet. 2009 Jun 15;18(12):2241-56. doi: 10.1093/hmg/ddp160. Epub 2009 Mar 31.

16.

Comparative gene mapping in cattle, Indian muntjac, and Chinese muntjac by fluorescence in situ hybridization.

Murmann AE, Mincheva A, Scheuermann MO, Gautier M, Yang F, Buitkamp J, Strissel PL, Strick R, Rowley JD, Lichter P.

Genetica. 2008 Nov;134(3):345-51. doi: 10.1007/s10709-008-9242-1. Epub 2008 Feb 19.

PMID:
18283540
17.

Serine protease inhibitor 6-deficient mice have increased neutrophil immunity to Pseudomonas aeruginosa.

Zhang M, Liu N, Park SM, Wang Y, Byrne S, Murmann AE, Bahr S, Peter ME, Olson ST, Belaaouaj A, Ashton-Rickardt PG.

J Immunol. 2007 Oct 1;179(7):4390-6.

18.

Serine protease inhibitor 6 protects cytotoxic T cells from self-inflicted injury by ensuring the integrity of cytotoxic granules.

Zhang M, Park SM, Wang Y, Shah R, Liu N, Murmann AE, Wang CR, Peter ME, Ashton-Rickardt PG.

Immunity. 2006 Apr;24(4):451-61.

19.

Local gene density predicts the spatial position of genetic loci in the interphase nucleus.

Murmann AE, Gao J, Encinosa M, Gautier M, Peter ME, Eils R, Lichter P, Rowley JD.

Exp Cell Res. 2005 Nov 15;311(1):14-26. Epub 2005 Oct 3.

PMID:
16202404
20.

Phosphorylation of FADD at serine 194 by CKIalpha regulates its nonapoptotic activities.

Alappat EC, Feig C, Boyerinas B, Volkland J, Samuels M, Murmann AE, Thorburn A, Kidd VJ, Slaughter CA, Osborn SL, Winoto A, Tang WJ, Peter ME.

Mol Cell. 2005 Aug 5;19(3):321-32.

21.

Characterization of nuclear compartments identified by ectopic markers in mammalian cells with distinctly different karyotype.

Scheuermann MO, Murmann AE, Richter K, Görisch SM, Herrmann H, Lichter P.

Chromosoma. 2005 May;114(1):39-53. Epub 2005 Mar 18.

PMID:
15776261
22.

Molecular ordering of the initial signaling events of CD95.

Algeciras-Schimnich A, Shen L, Barnhart BC, Murmann AE, Burkhardt JK, Peter ME.

Mol Cell Biol. 2002 Jan;22(1):207-20.

Supplemental Content

Loading ...
Support Center